Results 91 to 100 of about 10,001 (276)

Update of endoscopy in liver disease:More than just treating varices [PDF]

open access: yes, 2012
The management of complications in liver disease is often complex and challenging. Endoscopy has undergone a period of rapid expansion with numerous novel and specialized endoscopic modalities that are of increasing value in the investigation and ...
Hayes, Peter C.   +3 more
core   +2 more sources

RATIONAL FOR CONTINUING TERLIPRESSIN AFTER ENDOSCOPIC VARICEAL LIGATION IN ACUTE VARICEAL HAEMORRHAGE NEEDS FURTHER EVIDENCE: A PILOT STUDY [PDF]

open access: diamond, 2022
Ram C. Poudel   +5 more
openalex   +1 more source

Novel predictors of response to therapy with terlipressin and albumin in hepatorenal syndrome–acute kidney injury

open access: yesAnnals of gastroenterology : quarterly publication of the Hellenic Society of Gastroenterology, 2023
Background A combination of terlipressin and albumin is the first-line pharmacologic treatment for hepatorenal syndrome–acute kidney injury (HRS-AKI). We assessed the response rates to terlipressin–albumin therapy in patients with HRS-AKI and determined ...
V. Narayanan   +8 more
semanticscholar   +1 more source

FIGO guideline on liver disease and pregnancy

open access: yesInternational Journal of Gynecology &Obstetrics, Volume 170, Issue 1, Page 28-48, July 2025.
Abstract The number of women entering pregnancy with chronic liver disease is rising. Gestational liver disorders affect 3% of the pregnant population. Both can be associated with significant maternal and fetal morbidity and mortality. European guidance has recently been published to inform management.
Melanie Nana   +24 more
wiley   +1 more source

In vitro binding and receptor-mediated activity of terlipressin at vasopressin receptors V1 and V2

open access: yesJournal of Experimental Pharmacology, 2017
Khurram Jamil,1 Stephen Chris Pappas,2 Krishna R Devarakonda1 1Clinical Development, Mallinckrodt Pharmaceuticals, Bedminster, 2Orphan Therapeutics, LLC, Lebanon, NJ, USA Abstract: Terlipressin, a synthetic, systemic vasoconstrictor with selective ...
Jamil K, Pappas SC, Devarakonda KR
doaj  

Effectiveness of Adjunctive Drug Therapy to Endoscopic Stenting in Liver Cirrhosis Complicated by Refractory Variceal Bleeding

open access: yesНеотложная медицинская помощь
AIM OF THE STUDY. Comparative clinical analysis of the efficacy of terlipressin and octreotide as additional drug therapy to mechanical hemostasis with nitinol stent in patients with liver cirrhosis complicated by bleeding from esophageal varices ...
A. Yu. Anisimov, Yu. A. Anisimov
doaj   +1 more source

Effects of short-term simultaneous infusion of dobutamine and terlipressin in patients with septic shock: the DOBUPRESS study [PDF]

open access: yes, 2017
Background Terlipressin bolus infusion may reduce cardiac output and global oxygen supply. The present study was designed to determine whether dobutamine may counterbalance the terlipressin-induced depression in mixed-venous oxygen saturation (Svo2) in ...
Dünser, M.   +7 more
core  

Clinical course and prognostic factors of hepatorenal syndrome: A retrospective single-center cohort study [PDF]

open access: yes, 2013
AIM: To investigate clinical and biochemical features of hepatorenal syndrome (HRS), to assess short and long-term survival evaluating potential predictors of early mortality. METHODS: Sixty-two patients with liver cirrhosis and renal failure, defined as
Almasio, P.   +6 more
core   +1 more source

Efficacy and Safety of Vasopressin and Terlipressin in Preterm Neonates: A Systematic Review [PDF]

open access: gold, 2022
Abdulrahman Al-Saadi   +5 more
openalex   +1 more source

Terlipressin-Induced Skin Necrosis While Managing Hepatorenal Syndrome: A Rare Case Report From North India

open access: yesCureus, 2023
Terlipressin is an analogue of vasopressin and is often used in the treatment of bleeding esophageal varices and also in the treatment of hepatorenal syndrome associated with liver cirrhosis.
Sourav Sudan   +4 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy